Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZAPPHIRE: Zampilimab in Idiopathic Pulmonary Fibrosis
NCT07516951Phase 2Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 4
01
Overview
A Phase 2 trial of Zampilimab in idiopathic pulmonary fibrosis (IPF), sponsored by Chiesi Farmaceutici S.p.A.. Started Jul 2026; status: recruiting.
02
Drugs
Zampilimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07516951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516951.